In the News

French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress.   Specific terms of the deal were not disclosed.   Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....

Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation...

Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay.   The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is...

As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie...

BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.

September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the...

Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.  

Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.

Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.

Accomplished industry leaders join recently appointed CEO, Dr. Rolland Carlson, to expand on the comprehensive experience of the Board.

Immunexpress strengthens Board of Directors with key appointments.

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine.